Roche Lung Cancer Drug Tecentriq Rejected by U.K. Watchdog

(Bloomberg) -- Roche Holding AG’s Tecentriq was rejected by the U.K.’s health-cost overseer for treatment of late-stage lung cancer.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.